For Health Care Professionals Outside the US

 
 
 

Deepen response in your patients with relapsed and/or refractory multiple myeloma1

In a subgroup analysis, adding FARYDAK® (panobinostat) regimen more than doubled the rate of deep response (complete response/near complete response [CR/nCR])1

More than 1 in 5 patients who received at least 2 prior treatments, including bortezomib (BTZ) and an immunomodulatory drug (IMiD), had a deep response with FVD.1

FARYDAK response rates

CR was defined as absence of M protein in serum and urine by immunofixation for ≥6 weeks, <5% plasma cells in bone marrow, no increase in size or number of lytic bone lesions from baseline, and disappearance of soft tissue plasmacytomas (if present at baseline). All CR criteria apply to nCR, except that absence of serum and urine M protein cannot be confirmed by immunofixation.2

References:

  1. FARYDAK® (panobinostat). EU Summary of Product Characteristics. Novartis AG; April 2016.
  2. Kröger, N. The European Group for Blood and Marrow Transplantation: multiple myeloma. https://www.ebmt.org/Contents/Resources/Library/Slidebank/Documents/EBMT%202009%20SC%20Slide%20Bank/1211.pdf. Accessed July 22, 2015.

Ready to prescribe? Create a custom medicine tracker calendar for your patient